Genomics & Proteomics Archives - Evolution Search Partners

February 4, 2019

Categories

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]

October 24, 2018

Categories

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]

October 10, 2018

Categories

Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX

[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong third quarter, with over $3.18B raised by 26 companies across the globe, bringing the year-to-date total up […]

September 12, 2018

Categories

The Future of BioManufacturing: Automated Closed Systems for Cell & Gene Therapy Processes

August 10, 2018

Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Categories

News & Analysis

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]

June 4, 2018

Categories

The Future of BioManufacturing: In Silico Modelling

April 12, 2018

Categories

Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

[vc_row][vc_column][vc_column_text] Swiss CDMO Lonza recently opened the world’s biggest manufacturing plant to produce custom viruses for use in cell and gene therapies. The facility, based in […]

March 27, 2018

Categories

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]

February 20, 2018

Categories

2018 Global Drug Development IPO Analysis: $10.24B Raised in Strongest Year on Record

[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong year in 2018, with over $10.24B raised by 95 companies across 15 global exchanges. When compared to […]